| Large Scale, In Situ Isolation of Periplasmic IGF–I from E. coli RA Hart, PM Lester, DH Reifsnyder, JR Ogez, SE Builder Bio/technology 12 (11), 1113-1117, 1994 | 137 | 1994 |
| Protein composition of Vitreoscilla hemoglobin inclusion bodies produced in Escherichia coli. RA Hart, U Rinas, JE Bailey Journal of Biological Chemistry 265 (21), 12728-12733, 1990 | 92 | 1990 |
| Aqueous multiple-phase isolation of polypeptide S Builder, R Hart, P Lester, J Ogez, D Reifsnyder US Patent 5,407,810, 1995 | 58 | 1995 |
| End‐to‐end collaboration to transform biopharmaceutical development and manufacturing J Erickson, J Baker, S Barrett, C Brady, M Brower, R Carbonell, ... Biotechnology and Bioengineering 118 (9), 3302-3312, 2021 | 42 | 2021 |
| Refolding of misfolded insulin-like growth factor-I S Builder, R Hart, P Lester, D Reifsnyder US Patent 5,663,304, 1997 | 35 | 1997 |
| Purification and aqueous two-phase partitioning properties of recombinant Vitreoscilla hemoglobin RA Hart, JE Bailey Enzyme and microbial technology 13 (10), 788-795, 1991 | 35 | 1991 |
| A virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib drug substance intermediate, part 3: manganese-catalyzed asymmetric Epoxidation, crystallization, and … AJ Maloney, E Içten, G Capellades, MG Beaver, X Zhu, LR Graham, ... Organic Process Research & Development 24 (10), 1891-1908, 2020 | 33 | 2020 |
| A virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib drug substance intermediate, part 1: CDI-promoted amide bond formation E Içten, AJ Maloney, MG Beaver, DE Shen, X Zhu, LR Graham, ... Organic Process Research & Development 24 (10), 1861-1875, 2020 | 29 | 2020 |
| Refolding of polypeptides S Builder, R Hart, P Lester, D Reifsnyder US Patent 5,756,672, 1998 | 27 | 1998 |
| Use of multifactorial analysis to develop aqueous two-phase systems for isolation of non-native IGF-I. RA Hart, JR Ogez, SE Builder Bioseparation 5 (2), 113-121, 1995 | 27 | 1995 |
| Effect of environment on insulin‐like growth factor I refolding selectivity H RA, G DM, L PM, H Reifsnyder, B SE Biotechnology and applied biochemistry 20 (2), 217-232, 1994 | 27 | 1994 |
| Refolding of polypeptides like recombinant insulin-like growth factor IGF-I S Builder, R Hart, P Lester, D Reifsnyder US Patent 5,808,006, 1998 | 24 | 1998 |
| A virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib drug substance intermediate, part 2: Enone synthesis via a Barbier-type Grignard process E Içten, AJ Maloney, MG Beaver, X Zhu, DE Shen, JA Robinson, ... Organic Process Research & Development 24 (10), 1876-1890, 2020 | 23 | 2020 |
| Advancement in the modeling of pressure-flow for the guidance of development and scale-up of commercial-scale biopharmaceutical chromatography RN Keener III, EJ Fernandez, JE Maneval, RA Hart Journal of Chromatography A 1190 (1-2), 127-140, 2008 | 23 | 2008 |
| Effect of biosynthetic manipulation of heme on insolubility of Vitreoscilla hemoglobin in Escherichia coli RA Hart, PT Kallio, JE Bailey Applied and environmental microbiology 60 (7), 2431-2437, 1994 | 23 | 1994 |
| Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies JE Ladwig, XX Zhu, P Rolandi, R Hart, J Robinson, A Rydholm Biotechnology Progress 36 (5), e2993, 2020 | 16 | 2020 |
| Effectiveness of Upstream Barrier Technologies for Inactivation of Adventitious Contaminants of Cell Culture M Schleh, B Lawrence, T Park, S Rosenthal, R Hart, H Dehghani American Pharmaceutical Review 13 (7), 72, 2010 | 15* | 2010 |
| Refolding proteins using a chemically controlled redox state JE Shultz, R Hart, RN Keener III US Patent 8,952,138, 2015 | 14 | 2015 |
| Solubilization and regeneration of Vitreoscilla hemoglobin isolated from protein inclusion bodies RA Hart, JE Bailey Biotechnology and bioengineering 39 (11), 1112-1120, 1992 | 14 | 1992 |
| Development of advanced host cell protein enrichment and detection strategies to enable process relevant spike challenge studies RG Soderquist, M Trumbo, RA Hart, Q Zhang, GC Flynn Biotechnology Progress 31 (4), 983-989, 2015 | 13 | 2015 |
Richard D. BraatzEdwin R. Gilliland Professor, Massachusetts Institute of Technology在 mit.edu 的电子邮件经过验证
